APA (7th ed.) Citation

Pellegatta, S., Eoli, M., Cuccarini, V., Anghileri, E., Pollo, B., Pessina, S., . . . Finocchiaro, G. (2018). Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Pellegatta, Serena, et al. Survival Gain in Glioblastoma Patients Treated with Dendritic Cell Immunotherapy Is Associated with Increased NK but Not CD8+ T Cell Activation in the Presence of Adjuvant Temozolomide. Taylor & Francis Group, 2018.

MLA (9th ed.) Citation

Pellegatta, Serena, et al. Survival Gain in Glioblastoma Patients Treated with Dendritic Cell Immunotherapy Is Associated with Increased NK but Not CD8+ T Cell Activation in the Presence of Adjuvant Temozolomide. Taylor & Francis Group, 2018.